Advertisement

Topics

Companies Related to "TollLike Receptor Agonists Pipeline Insights 2017 Updated 30052017" [Most Relevant Company Matches] RSS

16:18 EDT 19th September 2018 | BioPortfolio

Here are the most relevant search results for "TollLike Receptor Agonists Pipeline Insights 2017 Updated 30052017" found in our extensive corporate database of over 50,000 company records.

Showing "TollLike Receptor Agonists Pipeline Insights 2017 Updated 30052017" Companies 1–25 of 1,500+

Relevant

Athenagen, Inc

Athenagen, Inc., located in South San Francisco, is engaged in the development of small-molecule drugs that act on the nicotinic acetylcholine (nACh) receptor pathway. The company's lead nACh receptor agonists and antagonists are being developed to treat diseases associated with enhanced or impaired angiogenesis and in diseases where cognitive deficit plays a significant role. Athenagen currently ...


Alexar Therapeutics, Inc.

Alexar Therapeutics, Inc. is focused on developing an innovative portfolio of Liver X receptor (LXR) agonists. For more information, visit www.alexartx.com.

Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's internally developed drug pipeline utilizes proprietary approaches to discover potent rigid conformers from flexible peptide starting points. Palatin's strategy is to develop p...


Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development is Dextofisopam for the treatment of IBS which has been developed through Phase 2b clinical trials. The Company also has a proprietary...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

Ziarco

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-3893787, an H4 receptor antagonist that has completed a Phase 1 multiple ascending dose study. A second clinical-stage, programme targets inflammatory disorders by inhibiting cyto...

Radius

RAD1901 is a potential first-in-class novel selective estrogen receptor modulator (SERM) under development at Radius for menopausal hot flashes. SERMs are small molecules that bind to and selectively modulate estrogen receptors. These molecules have the ability to stimulate or block estrogen's activity in different types of tissue, functioning as estrogen receptor agonists in some tissues and as e...

Inversago Pharma Inc.

A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), type 1 diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s techno...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has ...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

Receptor Biology Incorporated

Receptor Biology Inc. produce cloned receptors for pharmacology studies and drug discovery, products include adenosine, cannabinoid, dopamine, muscarinic, serotonin, opoid, bradykinin, transporter, wild type.

Naurex Inc.

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues now at The Falk Center for Molecular Therapeutics at Northwestern University, who discovered a new mechanism of action for modulating the NMDA receptor. Naurex has used these discoveries to generate novel chemical drug classes known a...

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.

Capitol Insights

Capitol Insights helps organizations develop and implement comprehensive public relations and government affairs programs to educate the public, motivate people and shape public policy.Capitol Insights helps clients understand how policy may move in the future because of changes in public opinion, political pressure and legal interpretation. Helping organizations make better decisions and build st...

QIAGEN GmbH

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Synaptic Pharmaceutical Corporation

Synaptic Pharmaceutical Corporation is a biotechnology company engaged in the development of a broad platform of enabling technology which it calls "human receptor- targeted drug design technology." The Company is utilizing this technology to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders. The Company and its collaborative part...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Transcend Insights and Humana Inc.

Transcend Insights, the population health technology company of Humana Inc. (NYSE: HUM), provides solutions that rise above data silos and connect care teams with the insights they need to succeed in a value-based care world. By leveraging its leading-edge approach to data aggregation, interoperability and analytics, Transcend Insights provides health syst...

QIAGEN N.V.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Naurex, Inc.

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues who discovered a new mechanism of action for modulating the NMDA receptor. Naurex has used these discoveries to generate novel chemical drug classes known as glycine site functional partial agonists (GFPAs). Naurex's first GFPA NMDA ...

Valify, Inc.

Valify, named as a Gartner “Cool Vendor” for Supply Chain Execution Technologies in 2017, is a purchased services technology solution that enables health care organizations to quickly identify spend, benchmark performance, and monitor savings in over 1,200 categories. With proprietary benchmarking analysis, market share insights, and customizable...

Prexton Therapeutics

Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders. Prexton Therapeutics has the expertise to design novel mGluR4 compounds as new treatment for Parkinson’s disease. One of the major objectives of research into new treatments for Parkinson’s disease is to find ...


More From BioPortfolio on "TollLike Receptor Agonists Pipeline Insights 2017 Updated 30052017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks